OTCMKTS:ARTH

Arch Therapeutics Stock Forecast, Price & News

$0.16

-0.01 (-5.99 %)

(As of 01/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$0.15

Now: $0.16▼

$0.16

50-Day Range

$0.13

MA: $0.16▼

$0.20

52-Week Range

$0.12

Now: $0.16▼

$0.26

Volume238,322 shs

Average Volume485,262 shs

Market Capitalization$30.31 million

P/E RatioN/A

Dividend YieldN/A

Beta0.11

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.

MarketRank^™

Overall MarketRank^™

1.16 out of 5 stars

Medical Sector

760th out of 1,558 stocks

Surgical & Medical Instruments Industry

79th out of 137 stocks

3.5 Analyst's Opinion

Consensus Rating
Arch Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $1.38, Arch Therapeutics has a forecasted upside of 775.8% from its current price of $0.16.
Amount of Analyst Coverage
Arch Therapeutics has received no research coverage in the past 90 days.

2.3 Community Rank

Outperform Votes
Arch Therapeutics has received 194 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Arch Therapeutics has received 219 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Arch Therapeutics has received 53.03% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Arch Therapeutics and other stocks. Vote “Outperform” if you believe ARTH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARTH will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Arch Therapeutics does not currently pay a dividend.
Dividend Growth
Arch Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Arch Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 12.16% of the stock of Arch Therapeutics is held by insiders.
Percentage Held by Institutions
Only 0.04% of the stock of Arch Therapeutics is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Arch Therapeutics are expected to decrease in the coming year, from ($0.03) to ($0.04) per share.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Surgical & medical instruments

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:ARTH

Previous SymbolNASDAQ:ARTH

CUSIPN/A

CIK1537561

Webwww.archtherapeutics.com

Phone617-431-2313

Employees7

Debt

Debt-to-Equity RatioN/A

Current Ratio3.32

Quick Ratio1.82

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value($0.01) per share

Price / Book-15.70

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-4,690,000.00

Net MarginsN/A

Return on EquityN/A

Return on Assets-159.31%

Miscellaneous

Outstanding Shares193,040,000

Market Cap$30.31 million

Next Earnings Date2/4/2021 (Estimated)

OptionableNot Optionable

$0.16

-0.01 (-5.99 %)

(As of 01/15/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive ARTH News and Ratings via Email

Sign-up to receive the latest news and ratings for ARTH and its competitors with MarketBeat's FREE daily newsletter.

Arch Therapeutics (OTCMKTS:ARTH) Frequently Asked Questions

How has Arch Therapeutics' stock price been impacted by COVID-19?

Arch Therapeutics' stock was trading at $0.2050 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ARTH stock has decreased by 23.4% and is now trading at $0.1570.
View which stocks have been most impacted by COVID-19.

Is Arch Therapeutics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arch Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Arch Therapeutics stock.
View analyst ratings for Arch Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Arch Therapeutics?

Wall Street analysts have given Arch Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Arch Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Arch Therapeutics' next earnings date?

Arch Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Arch Therapeutics.

How were Arch Therapeutics' earnings last quarter?

Arch Therapeutics, Inc. (OTCMKTS:ARTH) released its quarterly earnings results on Thursday, July, 23rd. The biotechnology company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of ($0.01) by $0.01.
View Arch Therapeutics' earnings history.

What price target have analysts set for ARTH?

2 equities research analysts have issued 1 year target prices for Arch Therapeutics' stock. Their forecasts range from $1.25 to $1.50. On average, they expect Arch Therapeutics' share price to reach $1.38 in the next twelve months. This suggests a possible upside of 775.8% from the stock's current price.
View analysts' price targets for Arch Therapeutics or view Wall Street analyst' top-rated stocks.

Who are some of Arch Therapeutics' key competitors?

Some companies that are related to Arch Therapeutics include Beyond Air (XAIR), Pro-Dex (PDEX), Nemaura Medical (NMRD), Apollo Endosurgery (APEN), Venus Concept (VERO), Brainsway (BWAY), SANUWAVE Health (SNWV), Spectral Medical (EDTXF), Nephros (NEPH), LENSAR (LNSR), Vivos (RDGL), Delcath Systems (DCTH), AIT Therapeutics (AITB), Sensus Healthcare (SRTS) and Nephros (NEPHD).
View all of ARTH's competitors.

What other stocks do shareholders of Arch Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arch Therapeutics investors own include Anavex Life Sciences (AVXL), POET Technologies (POETF), Aptose Biosciences (APTO), Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), SCYNEXIS (SCYX), Bellerophon Therapeutics (BLPH), Sorrento Therapeutics (SRNE), Biocept (BIOC) and Aurinia Pharmaceuticals (AUPH).

Who are Arch Therapeutics' key executives?

Arch Therapeutics' management team includes the following people:

Dr. Terrence W. Norchi, Co-Founder, Chairman, Pres, CEO & Sec. (Age 55, Pay $519.2k)
Mr. Richard E. Davis, CFO & Treasurer (Age 62, Pay $387.26k)
Dr. Rutledge Ellis-Behnke Ph.D., Co-Founder & Scientific Advisor
Dr. Steven A. Kates, VP of Technology
Dr. Elaine Whitmore, Regulatory Consultant & Advisor
Dr. Avtar S. Dhillon, Bus. Advisor (Age 59)
Mr. Daniel C. Wadsworth Jr., Advisor & Consultant of Wound Care Commercialization (Age 66)
Dr. Dmitry Nepomnayshy, Clinical Advisor

What is Arch Therapeutics' stock symbol?

Arch Therapeutics trades on the OTCMKTS under the ticker symbol "ARTH."

How do I buy shares of Arch Therapeutics?

Shares of ARTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Arch Therapeutics' stock price today?

One share of ARTH stock can currently be purchased for approximately $0.16.

How big of a company is Arch Therapeutics?

Arch Therapeutics has a market capitalization of $30.31 million. Arch Therapeutics employs 7 workers across the globe.

What is Arch Therapeutics' official website?

The official website for Arch Therapeutics is www.archtherapeutics.com.

How can I contact Arch Therapeutics?

Arch Therapeutics' mailing address is 235 WALNUT STREET SUITE 6, FRAMINGHAM MA, 01702. The biotechnology company can be reached via phone at 617-431-2313 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here